{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:25:09Z","timestamp":1788881109202,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100021069","name":"Indivior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.josat.2023.209155","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T12:36:18Z","timestamp":1693398978000},"page":"209155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies"],"prefix":"10.1016","volume":"154","author":[{"given":"Daniel","family":"Rutrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Learned","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Boyett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-5781","authenticated-orcid":false,"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2023.209155_bb0005","series-title":"Diagnostic and statistical manual of mental disorders: DSM-5","author":"American Psychiatric Association","year":"2013"},{"issue":"3","key":"10.1016\/j.josat.2023.209155_bb0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JCP.0000000000001195","article-title":"Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis","volume":"40","author":"Andorn","year":"2020","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1016\/j.josat.2023.209155_bb0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: A systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2023.209155_bb0020","unstructured":"Drug Enforcement Administration, 2022. National drug threat assessment. https:\/\/www.dea.gov\/sites\/default\/files\/2021-02\/DIR-008-21%202020%20National%20Drug%20Threat%20Assessment_WEB.pdf. (8) Accessed August 18, 2022."},{"key":"10.1016\/j.josat.2023.209155_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.drugalcdep.2017.03.013","article-title":"Effectiveness of treatment for opioid use disorder: A national, five-year, prospective, observational study in England","volume":"176","author":"Eastwood","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.209155_bb0030","doi-asserted-by":"crossref","unstructured":"Frost, M., Bailey, G.L, Lintzeris, N., Strang, J., Dunlop, A., Nunes, E.V., Jansen, J.B., Frey, L.C., Weber, B., Haber, P., Oosman, S., Kim, S., Tiberg, F., 2019. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. Addiction 114 (8), 1416\u20131426.","DOI":"10.1111\/add.14636"},{"issue":"10","key":"10.1016\/j.josat.2023.209155_bb0035","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.josat.2023.209155_bb0040","first-page":"CD004145","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection","volume":"8","author":"Gowing","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10173","key":"10.1016\/j.josat.2023.209155_bb0045","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.josat.2023.209155_bb0050","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction"},{"issue":"9358","key":"10.1016\/j.josat.2023.209155_bb0055","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.josat.2023.209155_bb0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study","volume":"169","author":"Larochelle","year":"2018","journal-title":"Annals of Internal Medicine"},{"issue":"10118","key":"10.1016\/j.josat.2023.209155_bb0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.josat.2023.209155_bb0070","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1097\/ADM.0000000000000647","article-title":"Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study","volume":"14","author":"Ling","year":"2020","journal-title":"Journal of Addiction Medicine"},{"issue":"6","key":"10.1016\/j.josat.2023.209155_bb0075","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/ADM.0000000000000517","article-title":"Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study","volume":"13","author":"Ling","year":"2019","journal-title":"Journal of Addiction Medicine"},{"issue":"12","key":"10.1016\/j.josat.2023.209155_bb0080","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Molecular Psychiatry"},{"issue":"3","key":"10.1016\/j.josat.2023.209155_bb0085","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2009","author":"Mattick","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2023.209155_bb0090","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.josat.2023.209155_bb0095","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40501-015-0038-5","article-title":"Outcome measures in medication trials for substance use disorders","volume":"2","author":"McCann","year":"2015","journal-title":"Current Treatment Options in Psychiatry"},{"issue":"2","key":"10.1016\/j.josat.2023.209155_bb0100","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/add.13193","article-title":"Impact of treatment for opioid dependence on fatal drug-related poisoning: A national cohort study in England","volume":"111","author":"Pierce","year":"2016","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.josat.2023.209155_bb0105","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/00952990701523698","article-title":"Quality of life among heroin users on buprenorphine versus methadone maintenance","volume":"33","author":"Ponizovsky","year":"2007","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.josat.2023.209155_bb0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13722-021-00223-z","article-title":"Prior national drug abuse treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 \u201coptimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)\u201d","volume":"16","author":"Shulman","year":"2021","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.josat.2023.209155_bb0115","doi-asserted-by":"crossref","first-page":"J1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.josat.2023.209155_bb0120","series-title":"SUBLOCADE (buprenorphine), Australian product information","year":"2022"},{"key":"10.1016\/j.josat.2023.209155_bb0125","series-title":"SUBLOCADE\u00ae (buprenorphine extended-release injection), for subcutaneous use. Product monograph","year":"2022"},{"key":"10.1016\/j.josat.2023.209155_bb0130","series-title":"SUBLOCADE\u00ae (buprenorphine extended-release) injection, for subcutaneous use, CIII. Full prescribing information","year":"2022"},{"issue":"2","key":"10.1016\/j.josat.2023.209155_bb0135","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: Assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatric Services"},{"issue":"1","key":"10.1016\/j.josat.2023.209155_bb0140","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Diseases"},{"issue":"12","key":"10.1016\/j.josat.2023.209155_bb0145","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","article-title":"Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users","volume":"174","author":"Tsui","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"8","key":"10.1016\/j.josat.2023.209155_bb0150","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1176\/appi.ajp.2018.17101174","article-title":"Neuroscience of addiction: Relevance to prevention and treatment","volume":"175","author":"Volkow","year":"2018","journal-title":"The American Journal of Psychiatry"},{"issue":"3","key":"10.1016\/j.josat.2023.209155_bb0155","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QAI.0000000000000165","article-title":"HIV risk reduction with buprenorphine-naloxone or methadone: Findings from a randomized trial","volume":"66","author":"Woody","year":"2014","journal-title":"Journal of Acquired Immune Deficiency Syndromes"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923002060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923002060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:39:47Z","timestamp":1762652387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923002060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":31,"alternative-id":["S2949875923002060"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.209155","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.209155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209155"}}